Bibiliography
- Global Initiative for Asthma, National Institute of Health, National Heart Lung and Blood Institute, NHLBI/WHO Workshop Report. Global strategy for asthma management and prevention. Bethesda, MD: National Heart, Lung and Blood Institute. NHLBI/WHO workshop report no. 02-3659 January 1995 updated 2006
- Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003;123(5):1480-7
- Tal A, Simon G, Vermeulen JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002;34(5):342-50
- Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337(20):1405-11
- Ringdal N, Chuchalin A, Chovan L, et al. Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd) Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. Respir Med 2002;96(11):851-61
- Bateman ED, Bantje TA, Joao Gomes M, et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2003;2(3):275-81
- Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344(8917):219-24
- Rosenhall L, Elvstrand A, Tilling B, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 2003;97(6):702-8
- Huchon G, Fabbri LM. CFC phase-out and the Chiesi solution. Respiration 2005;72(Suppl 1):1-2
- Tulic MK, Hamid Q. New insights into the pathophysiology of the small airways in asthma. Clin Chest Med 2006;27(1):41-52, vi
- Brogden RN, Heel RC, Speight TM, Avery GS. Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 1984;28(2):99-126
- Faulds D, Hollingshead LM, Goa KL. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42(1):115-37
- Dhillon S, Keating GM. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs 2006;66(11):1475-83; discussion 84-5
- Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997;100(1):44-51
- Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000;106(6):1209-26
- Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm Pharmacol Ther 2007;20(3):290-303
- Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 2004;1(4):356-63
- Kips JC, Pauwels RA. Long-acting inhaled beta(2)-agonist therapy in asthma. Am J Respir Crit Care Med 2001;164(6):923-32
- Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19(1):182-91
- Scott MG, Swan C, Wheatley AP, Hall IP. Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene. Br J Pharmacol 1999;126(4):841-4
- Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274(2):1005-10
- Farmer P, Pugin J. Beta-adrenergic agonists exert their “anti-inflammatory” effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 2000;279(4):L675-82
- Razzetti R, Bergamaschi M, Villetti G, et al. Formoterol and beclomethasone dipropionate interact positively in antagonising bronchoconstriction and inflammation in the lung. Pharmacol Res 2007;55(5):426-32.
- Profita M, Gagliardo R, Di Giorgi R, et al. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy 2005;60(3):323-9
- Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001;51(5):400-9
- Foe K, Brown KF, Seale JP. Comparative kinetics of metabolism of beclomethasone propionate esters in human lung homogenates and plasma. J Pharm Sci 2000;89(9):1143-50
- Lecaillon JB, Kaiser G, Palmisano M, et al. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. Eur J Clin Pharmacol 1999;55(2):131-8
- Poli G, Acerbi D, Nollevaux F. Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers. Eur Respir J 2006;28(Suppl 50):P3869 (Abstract). Poster presented at the16th Annual Congress of the European Respiratory Society; 2006 September 2-6; Munich
- Piccinno A, Borrill Z, Poli G, et al. Tolerability of high cumulative doses of a new fixed combination of beclomethasone dipropionate/formoterol in asthmatic patients. Eur Respir J 2006;28(Suppl 50):P1815 (Abstract). Poster presented at the16th Annual Congress of the European Respiratory Society; 2006 September 2-6; Munich
- Rigamonti E, Kottakis I, Pelc M, et al. Comparison of a new extrafine beclomethasone dipropionate HFA 134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma. Eur Respir J 2006;28(Suppl 50):P1236 (Abstract). Poster presented at the16th Annual Congress of the European Respiratory Society; 2006 September 2-6; Munich
- Bonnet-Gonod F, Kottakis I, Hofman T, et al. Beclomethasone diproprionate/formoterol in a single inhaler improves lung function and clinically meaningful outcomes in moderate to severe asthma. Eur Respir J 2006;28(Suppl 50):P1230 (Abstract). Poster presented at the16th Annual Congress of the European Respiratory Society; 2006 September 2-6; Munich
- Papi A, Paggiaro PL, Nicolini G, et al. Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group: beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007;29(4):682-9
- Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007;62(10):1182-8.
- Cremonesi G, Nicolini G, Papi A, et al. Trattamento farmacologico in pazienti con asma bronchiale di grado moderato-grave: analisi di minimizzazione dei costi. Accepted for pPoster presentation presented at the VIII national UIP congress, 4-7 December 2007, Florence, Italy (Abstract)
- Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159(9):941-55
- Jenkins C, Kolarikova R, Kuna P, et al. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 2006;11(3):276-86
- Noonan M, Rosenwasser LJ, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 2006;66(17):2235-54
- Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999;93(12):876-84
- Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. Can Respir J 1999;6(1):45-51
- Van Schayck CP, Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 1): an update of clinical experience in adults. Int J Clin Pract 2004;58(7):678-88
- Tarsin WY, Pearson SB, Assi KH, Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm 2006;316(1-2):131-7
- Nagel MW, Wiersema KJ, Bates SL, Mitchell JP. Performance of large- and small-volume valved holding chambers with a new combination long-term bronchodilator/anti-inflammatory formulation delivered by pressurized metered dose inhaler. J Aerosol Med 2002;15(4):427-33